Three-year clinical experience with the long-acting injectable formulation of the atypical antipsychotic risperidone
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1744-859X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Three-year clinical experience with the long-acting injectable formulation of the atypical antipsychotic risperidone ; volume:7 ; number:1 ; day:17 ; month:04 ; year:2008 ; pages:1 ; date:4.2008
Annals of general psychiatry ; 7, Heft 1 (17.04.2008), 1, 4.2008
- Creator
-
Leotsakou, Christina
Kessidou, Sofia
Kalogeropoulou, Aikaterini
Fotara, Ioanna
Robotis, Perikles
Karkatzouli, Christina
Gousis, Demetrios
Demetriades, Athanasios
Giovanoglou, Maria
Paterakis, Perikles
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/1744-859X-7-S1-S131
- URN
-
urn:nbn:de:101:1-2019071821340809392857
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Leotsakou, Christina
- Kessidou, Sofia
- Kalogeropoulou, Aikaterini
- Fotara, Ioanna
- Robotis, Perikles
- Karkatzouli, Christina
- Gousis, Demetrios
- Demetriades, Athanasios
- Giovanoglou, Maria
- Paterakis, Perikles
- SpringerLink (Online service)
Other Objects (12)
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia
Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders
Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs
Attitudes of European physicians towards the use of long-acting injectable antipsychotics
Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
Long-Acting Injectable Antipsychotics in a Prescription Claims Data Source: A Validation Study
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia
Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders
Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs
Attitudes of European physicians towards the use of long-acting injectable antipsychotics
Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
Long-Acting Injectable Antipsychotics in a Prescription Claims Data Source: A Validation Study
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia
Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders
Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs
Attitudes of European physicians towards the use of long-acting injectable antipsychotics
Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors